We speak with Uniseed CEO, Peter Devine, about the current ESG investment landscape, their recent collaboration with UniSuper and an unusual passion.

We talk to Race Oncology's CSO, Dr Daniel Tillett, about the early days of Race, the progress that the Company has made with its drug Zantrene®, and what success could mean for the future landscape of cancer treatments.

Our Communications Director, Cherie Hartley, talks with AdAlta's CEO & M.D. Dr Tim Oldham, who takes us inside the mind of a biotech company. He discussed the importance of focus for a platform company, explains why making decisions on a day-to-day basis is so crucial for risk reduction and why they're investing in supporting core strategies as well as their target product profile.